NKTR vs. PCRX, OMER, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, and BMY
Should you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include Pacira BioSciences (PCRX), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), and Bristol Myers Squibb (BMY). These companies are all part of the "pharmaceuticals" industry.
Nektar Therapeutics vs. Its Competitors
Pacira BioSciences (NASDAQ:PCRX) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.
In the previous week, Nektar Therapeutics had 23 more articles in the media than Pacira BioSciences. MarketBeat recorded 25 mentions for Nektar Therapeutics and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.87 beat Nektar Therapeutics' score of 0.72 indicating that Pacira BioSciences is being referred to more favorably in the media.
99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by insiders. Comparatively, 5.3% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Pacira BioSciences has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
Pacira BioSciences has a net margin of -14.78% compared to Nektar Therapeutics' net margin of -152.49%. Pacira BioSciences' return on equity of 13.78% beat Nektar Therapeutics' return on equity.
Pacira BioSciences has higher revenue and earnings than Nektar Therapeutics. Pacira BioSciences is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Pacira BioSciences currently has a consensus target price of $26.44, suggesting a potential upside of 13.96%. Nektar Therapeutics has a consensus target price of $84.17, suggesting a potential upside of 241.45%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Pacira BioSciences.
Summary
Pacira BioSciences beats Nektar Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Nektar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nektar Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NKTR) was last updated on 7/3/2025 by MarketBeat.com Staff
Free NKTR Stock Alerts